Atom Investors’s ProQR Therapeutics PRQR Stock Holding History

Atom Investors’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.2K	Hold	13,107	–	–	﹤0.01%	641
2025 Q4	$26.5K	Hold	13,107	–	–	﹤0.01%	552
2025 Q3	$27.9K	Hold	13,107	–	–	﹤0.01%	581
2025 Q2	$26.7K	Hold	13,107	–	–	﹤0.01%	584
2025 Q1	$17.4K	Hold	13,107	–	–	﹤0.01%	485
2024 Q4	$34.7K	Hold	13,107	–	–	﹤0.01%	476
2024 Q3	$23.9K	Hold	13,107	–	–	﹤0.01%	454
2024 Q2	$21.8K	Hold	13,107	–	–	﹤0.01%	455
2024 Q1	$30K	Hold	13,107	–	–	﹤0.01%	547
2023 Q4	$26K	Hold	13,107	–	–	﹤0.01%	437
2023 Q3	$17K	Hold	13,107	–	–	﹤0.01%	420
2023 Q2	$21.2K	Hold	13,107	–	–	0.01%	278
2023 Q1	$27.9K	Sell	13,107 -5,415	-29%	-$16.6K	0.02%	241
2022 Q4	$68.5K	Sell	18,522 -10,299	-36%	-$13.5K	0.03%	201
2022 Q3	$21K	Sell	28,821 -1,601	-5%	-$1.29K	0.01%	271
2022 Q2	$24K	Hold	30,422	–	–	0.01%	245
2022 Q1	$28K	Buy	+30,422	New	+$102K	0.01%	184

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Atom Investors's PRQR Position: Q1 2026 in Review

Atom Investors held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 13,107 shares worth $21.2K. The position accounts for ﹤0.01% of the portfolio, ranked #641.

Atom Investors first reported a position in PRQR in Q1 2022 and has held it in 17 quarters since. The position peaked at $68.5K in Q4 2022. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Atom Investors held 13,107 shares of ProQR Therapeutics worth $21.2K as of Q1 2026.
Atom Investors left its ProQR Therapeutics share count unchanged in Q1 2026.
ProQR Therapeutics made up ﹤0.01% of Atom Investors's portfolio in Q1 2026, its #641 holding.
Atom Investors first reported a position in ProQR Therapeutics in Q1 2022 and has held it in 17 quarters since.
Atom Investors's ProQR Therapeutics position peaked at $68.5K in Q4 2022.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.